NCCN 2014 GUIDELINES

recommend use of ondansetron in patients with highly and moderately emetogenic cancer chemotherapy-induced and radiotherapy-induced nausea and vomiting.13

ZUPLENZ DELIVERS THE TRUSTED EFFICACY
of ondansetron for patients receiving HEC

 

ZUPLENZ consistently achieved complete antiemetic response in HEC11

HEC-66

66%

of patients receiving HEC did not experience emesis, need rescue antiemetic therapy, or withdraw from the study11

 

ZUPLENZ was
SAFE AND WELL TOLERATED
for patients receiving HEC1

The most common adverse drug reactions (≥5%) reported in clinical trials of patients receiving ondansetron for prevention of nausea and vomiting associated with cancer chemotherapy or radiotherapy were headache, malaise/fatigue, constipation, and diarrhea.1